Repositioning FDA-Approved Sulfonamide-Based Drugs as Potential Carbonic Anhydrase Inhibitors in <i>Trypanosoma cruzi</i>: Virtual Screening and In Vitro Studies

Repositioning FDA-Approved Sulfonamide-Based Drugs as Potential Carbonic Anhydrase Inhibitors in <i>Trypanosoma cruzi</i>: Virtual Screening and In Vitro Studies

<b>Background/Objectives:</b> α-carbonic anhydrase (α-TcCA) has emerged as a promising drug target in <i>T. cruzi</i>, the causative agent of Chagas disease in the Americas. Sulfonamides, known inhibitors of CAs, bind to the zinc ion on the enzyme’s active site. This study pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Eyra Ortiz-Pérez, Adriana Moreno-Rodríguez, Timoteo Delgado-Maldonado, Jessica L. Ortega-Balleza, Alonzo González-González, Alma D. Paz-González, Karina Vázquez, Guadalupe Avalos-Navarro, Simone Giovannuzzi, Claudiu T. Supuran, Gildardo Rivera
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Pharmaceuticals
Subjects:
<i>Trypanosoma cruzi</i>
carbonic anhydrase
drug repurposing
virtual screening
molecular docking
Online Access:https://www.mdpi.com/1424-8247/18/5/669
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/18/5/669

Similar Items